|
Idiopathic Pulmonary Fibrosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
Moreover, patients with the MUC5B polymorphism show more severe coughing as MUC5B encodes for the dominant mucin in the honeycomb cysts of IPF patients.
|
30269188 |
2019 |
|
Idiopathic Pulmonary Fibrosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
MUC5B promoter rs868903 polymorphism and TLs were associated with radiographic extent and survival in a Chinese IPF cohort.
|
31653936 |
2019 |
|
Idiopathic Pulmonary Fibrosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, genetic variants of TOLLIP, MUC-5B, and other genes associated with a differential response to treatment and with the development and/or the prognosis of IPF are reported.
|
30526140 |
2019 |
|
Idiopathic Pulmonary Fibrosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Secreted mucins (MUC2, MUC5AC, MUC5B, MUC6-8 and MUC19) are released to the extracellular medium and recent evidence has shown that a promoter polymorphism in the secreted mucin MUC5B is associated with IPF risk.
|
31514468 |
2019 |
|
Idiopathic Pulmonary Fibrosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
In a study of idiopathic pulmonary fibrosis, we reverse a paradoxical association of the strong susceptibility gene MUC5B with increased survival, suggesting instead a significant association with decreased survival.
|
30952951 |
2019 |
|
Idiopathic Pulmonary Fibrosis
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
This work has important implications for further exploration of the mechanisms of overexpression of MUC5B in IPF, and future personalized treatment.
|
31309122 |
2019 |
|
Idiopathic Pulmonary Fibrosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
XBP1S Regulates MUC5B in a Promoter Variant-Dependent Pathway in Idiopathic Pulmonary Fibrosis Airway Epithelia.
|
30973754 |
2019 |
|
Idiopathic Pulmonary Fibrosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
Moreover, focusing on MUC5B may provide a unique opportunity to define the early molecular events that lead to, and potentially prevent, the development of IPF.
|
30431344 |
2018 |
|
Idiopathic Pulmonary Fibrosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, genetic variants of TOLLIP, MUC5B, and other genes are associated with a differential response to treatment and with the development and/or the prognosis of IPF.
|
29408012 |
2018 |
|
Idiopathic Pulmonary Fibrosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that mucociliary dysfunction might play a causative role in bleomycin-induced pulmonary fibrosis in mice overexpressing Muc5b, and that MUC5B in distal airspaces is a potential therapeutic target in humans with IPF.
|
30560893 |
2018 |
|
Idiopathic Pulmonary Fibrosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We found that the MUC5B promoter variant was associated with RA-ILD and more specifically associated with evidence of usual interstitial pneumonia on imaging.
|
30345907 |
2018 |
|
Idiopathic Pulmonary Fibrosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In aggregate, our findings indicate that the MUC5B promoter variant is associated with higher C3 expression and suggest that the complement system may contribute to the pathogenesis of IPF.
|
29565179 |
2018 |
|
Idiopathic Pulmonary Fibrosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study.
|
29891356 |
2018 |
|
Idiopathic Pulmonary Fibrosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We identified a novel genome-wide significant signal of association with IPF susceptibility near A-kinase anchoring protein 13 (AKAP13; rs62025270, odds ratio [OR] 1·27 [95% CI 1·18-1·37], p=1·32 × 10<sup>-9</sup>) and confirmed previously reported signals, including in mucin 5B (MUC5B; rs35705950, OR 2·89 [2·56-3·26], p=1·12 × 10<sup>-66</sup>) and desmoplakin (DSP; rs2076295, OR 1·44 [1·35-1·54], p=7·81 × 10<sup>-28</sup>).
|
29066090 |
2017 |
|
Idiopathic Pulmonary Fibrosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A promoter variant in MUC5B, rs35705950, was previously found to be strongly associated with the incidence of idiopathic pulmonary fibrosis (IPF) and also the overall survival (OS) of such patients.
|
28189065 |
2017 |
|
Idiopathic Pulmonary Fibrosis
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Regulation of MUC5B Expression in Idiopathic Pulmonary Fibrosis.
|
28272906 |
2017 |
|
Idiopathic Pulmonary Fibrosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
We found MUC5B MAFs in our IIP cohort similar to published frequencies for subjects with familial and sporadic IPF.
|
29206633 |
2017 |
|
Idiopathic Pulmonary Fibrosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We measured two common single-nucleotide polymorphisms associated with IPF (MUC5B rs35705950 and TOLLIP rs5743890) and telomere length in peripheral blood leucocytes, and assessed their associations with chronic hypersensitivity pneumonitis risk, survival, and clinical, radiographic, and pathological features.
|
28648751 |
2017 |
|
Idiopathic Pulmonary Fibrosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In spIPF carriership of MUC5B minor allele did not influence survival.
|
26699835 |
2016 |
|
Idiopathic Pulmonary Fibrosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We have previously found that 1) a common gain-of-function promoter variant in MUC5B rs35705950 is the strongest risk factor (genetic and otherwise), accounting for 30-35% of the risk of developing IPF, a disease that was previously considered idiopathic; 2) the MUC5B promoter variant can potentially be used to identify individuals with preclinical pulmonary fibrosis and is predictive of radiologic progression of preclinical pulmonary fibrosis; and 3) MUC5B may be involved in the pathogenesis of pulmonary fibrosis with MUC5B message and protein expressed in bronchiolo-alveolar epithelia of IPF and the characteristic IPF honeycomb cysts.
|
27630174 |
2016 |
|
Idiopathic Pulmonary Fibrosis
|
0.700 |
Biomarker
|
disease |
BEFREE |
To determine whether single-nucleotide polymorphisms (SNPs) within TOLLIP and MUC5B modify the effect of interventions in subjects participating in the Evaluating the Effectiveness of Prednisone, Azathioprine, and N-Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis (PANTHER-IPF) clinical trial.
|
26331942 |
2015 |
|
Idiopathic Pulmonary Fibrosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The MUC5B promoter SNP rs35705950 was associated with IPF in the Mexican (OR = 7.36, P = .0001), but not the Korean (P = .99) cohort.
|
25275363 |
2015 |
|
Idiopathic Pulmonary Fibrosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
MUC5B promoter polymorphism in Japanese patients with idiopathic pulmonary fibrosis.
|
25581455 |
2015 |
|
Idiopathic Pulmonary Fibrosis
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Expression of MUC5B is also highly correlated with expression of cilium genes in IPF lung.
|
26595739 |
2015 |
|
Idiopathic Pulmonary Fibrosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The MUC5B rs35705950 T/G polymorphism confers susceptibility to IPF in Europeans and Asians, but is not associated with susceptibility to CTD-ILD.
|
25926289 |
2015 |